S-H.I. Ou - Concepedia

Author

S-H.I. Ou

University of California, Irvine

Also Known As

S I. Ou, S Ou, S-H I Ou, S-H. Ignatius Ou, S-H.I. Ou, S. I. Ou, S. Ou, S.I. Ou

Publications

870

Citations

H-Index

Concepts

All Affiliations

University of California, Irvine Memorial Sloan Kettering Cancer Center Massachusetts General Hospital Roche (Switzerland)Virginia Cancer Specialists

About

S-H.I. Ou is an author at University of California, Irvine specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	790
2	Immunology	2	2	97
3	Public Health	1	1	20
4	Cell Biology	1	1	135
5	Epidemiology	1	1	20

S-H.I. Ou

Publications

790

Citations

H-Index

Page 1

	Year	Citations
Natural History of Stage I Non-Small Cell Lung Cancer Dan J. Raz, Jason A. Zell, S-H.I. Ou, CHEST Journal MedicineNatural HistoryPathologyBronchial NeoplasmPulmonary Blastoma	2007	322
Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with <i>ALK-</i>positive non-small cell lung cancer (NSCLC). D. Ross Camidge, Yung‐Jue Bang, E.L. Kwak, Journal of Clinical Oncology Progression-free SurvivalAlk-positive NsclcPart 2MedicinePharmacology	2011	135
Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). Y. Bang, E.L. Kwak, Alice T. Shaw, Journal of Clinical Oncology PharmacotherapyPre-clinical PharmacologyNeuro-oncologyOncologyMetronomic Therapy	2010	135
LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation Rona Yaeger, Melissa L. Johnson, Alexander I. Spira, Annals of Oncology Gastrointestinal OncologyLba6 Krystal-1MedicineImmunologyColorectal Cancer	2021	74
Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. Alice T. Shaw, B.Y. Yeap, Benjamin Solomon, Journal of Clinical Oncology Prognostic EvaluationMedicineAlk-positive NsclcAlk+ NsclcPharmacology	2011	38
LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation S.J. Klempner, J. Weiss, M. Pelster, Annals of Oncology Lba24 Krystal-1Gastrointestinal OncologyMedicineImmunologyPathology	2022	23
Epidemiology study of never-smokers with non-small cell lung cancer (NSCLC): High percentages of Asian and Hispanic female never-smokers and the significance of Asian ethnicity S-H.I. Ou, Argyrios Ziogas, Jason A. Zell Journal of Clinical Oncology EthnicityCancer ManagementEpidemiology Of CancerPathologySocial Determinants Of Health	2008	20
OA02.03 Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer: Phase 2 Study Cohort EXP-6 S-H.I. Ou, Alice T. Shaw, G. Riely, Journal of Thoracic Oncology Study Cohort Exp-6MedicinePathologyBronchial NeoplasmCancer Treatment	2018	18
Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study Shirish M. Gadgeel, Solange Peters, Tony Mok, Annals of Oncology PharmacologyPharmacotherapyAlex StudyInnovative TreatmentMedicine	2017	14
Alectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study Tony Mok, Solange Peters, D. Ross Camidge, Annals of Oncology OncologyPathologyBronchial NeoplasmVs CrizotinibAlex Study	2017	11

Page 1